Literature DB >> 25791707

Magnetic resonance imaging in the evaluation of clinical treatment of otospongiosis: a pilot study.

Andy de Oliveira Vicente1, Sujana S Chandrasekhar2, Helio K Yamashita3, Oswaldo Laercio M Cruz3, Flavia A Barros3, Norma O Penido3.   

Abstract

OBJECTIVES: To evaluate the applicability of magnetic resonance imaging (MRI) as a method for monitoring the activity of otospongiotic lesions before and after clinical treatment. STUDY
DESIGN: Prospective, randomized, controlled, double-blind study.
SETTING: One single tertiary care institution in a large, cosmopolitan city.
METHODS: Twenty-six patients (n = 42 ears) with clinical, audiometric, and tomographic diagnosis of otosclerosis were enrolled. If computed tomography (CT) demonstrated active lesions, these patients underwent MRI to detect otospongiotic foci, seen as areas of gadolinium enhancement. Patients were divided into 3 groups and received treatment with placebo, sodium alendronate, or sodium fluoride for 6 months. After this period, clinical and audiometric evaluations and a second MRI were performed. Each MRI was evaluated by both a neuroradiologist and an otolaryngologist in a subjective (visual) and objective (using specific eFilm Workstation software) manner.
RESULTS: Otospongiosis was most predominantly identified in the region anterior to the oval window, and this site was reliable for comparing pre- and posttreatment scans. The patients in the alendronate and sodium fluoride groups had MRI findings that suggested a decrease in activity of otospongiotic lesions, more relevant in the alendronate group. These findings were statistically significant for both subjective and objective MRI evaluations.
CONCLUSIONS: MRI shows higher sensitivity than clinical or audiometric assessment for detecting reduction in activity of otospongiosis. The objective MRI evaluation based on software analysis was the most accurate method of monitoring clinical treatment response in otospongiosis. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2015.

Entities:  

Keywords:  hearing loss; magnetic resonance imaging; otosclerosis; otospongiosis; sodium alendronate; sodium fluoride

Mesh:

Substances:

Year:  2015        PMID: 25791707     DOI: 10.1177/0194599815574698

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  3D fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging at different stages of otosclerosis.

Authors:  Stefano Berrettini; Francesco Lombardo; Luca Bruschini; Annalisa Ciabotti; Canapicchi Raffaello; Francesca Forli
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-06       Impact factor: 2.503

2.  3D-Flair sequence at 3T in cochlear otosclerosis.

Authors:  Francesco Lombardo; Sara De Cori; Gayane Aghakhanyan; Domenico Montanaro; Daniele De Marchi; Francesca Frijia; Susanna Fortunato; Francesca Forli; Dante Chiappino; Stefano Berrettini; Raffaello Canapicchi
Journal:  Eur Radiol       Date:  2016-01-08       Impact factor: 5.315

Review 3.  Role of MRI as first-line modality in the detection of previously undiagnosed otosclerosis: a single tertiary institute experience.

Authors:  Bela Purohit; Katya Op de Beeck; Robert Hermans
Journal:  Insights Imaging       Date:  2020-05-19

4.  Imaging Studies in Otosclerosis: An Up-to-date Comprehensive Review.

Authors:  Lucas Resende Lucinda Mangia; Luiz Otávio de Mattos Coelho; Bettina Carvalho; Adriana Kosma Pires de Oliveira; Rogerio Hamerschmidt
Journal:  Int Arch Otorhinolaryngol       Date:  2020-09-24

Review 5.  Bisphosphonate therapy in otosclerosis: A scoping review.

Authors:  René E Zimmerer; Robert E Africa; Zack K Westenhaver; Brian J McKinnon
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-06

6.  Cochlear Lymph Fluid Signal Increase in Patients with Otosclerosis after Intravenous Administration of Gadodiamide.

Authors:  Shinji Naganawa; Hisashi Kawai; Toshiaki Taoka; Kojiro Suzuki; Shingo Iwano; Hiroko Satake; Michihiko Sone; Mitsuru Ikeda
Journal:  Magn Reson Med Sci       Date:  2016-02-03       Impact factor: 2.471

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.